REHOVOT, Israel, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today financial results for the three and six months ended June 30, 2016.
Clinical, business and corporate developments for the three month ended June 30, 2016 and to date:
* The Phase 3 trial for lead drug candidate FMX101 in patients with moderate-to-severe acne which commenced in May 2016, is progressing as expected. The Company expects to release topline results during the first half of 2017.
Clinical, business and corporate developments for the three month ended June 30, 2016 and to date:
* The Phase 3 trial for lead drug candidate FMX101 in patients with moderate-to-severe acne which commenced in May 2016, is progressing as expected. The Company expects to release topline results during the first half of 2017.
